CARLSMED, INC.
No SEC Form 4 filings for $CARL in the last 30 days.
See all $CARL insider activity →Carlsmed (NASDAQ:CARL) discussed a CMS final rule issued July 31 that creates new MS-DRG codes for aprevo lumbar procedures, effective Oct. 1, 2026, replacing 11 codes. Management expects no material impact on 2H 2026 results. Q2 gross margin rose to 76.8% and GAAP net loss widened to $10.5M. Cash and investments were $89.3M at June 30.
CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 carl-ex99_1.htm EX-99.1 EX-99.1 Carlsmed ® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 milli
The article provides financial information for Carlsmed, Inc. (LS:A41CM7) on TradingView. It shows the total operating expenses for the company, accessible through various financial data providers like ICE Data Services and FactSet. The content primarily focuses on the display of operating expenses within the TradingView platform.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CARL (CARLSMED, INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CARL coverage spans financial news and earnings.
CMS MS-DRG code changes are a reimbursement tailwind narrative, but management explicitly guides no material impact on 2H 2026 results; near-term focus stays on launches and cost/margin trajectory.
Guidance raise plus strong adoption and gross margin expansion are likely to support near-term sentiment and estimates.
The reported total operating expenses for Carlsmed, Inc. are provided, but without context on current expenses or industry benchmarks, the direct impact on stock price is limited.
Limited financial data restricts comprehensive evaluation of Carlsmed, Inc.'s current valuation and performance.
The substantial 26.4% reduction in short interest suggests decreased bearish sentiment, possibly signaling a bullish outlook. Increased institutional holdings reinforce this view. However, the 'Hold' consensus and mixed analyst targets imply cautious optimism. Technical indicators and current price levels are unavailable, limiting precise short-term predictions.
alphai scores every news story that mentions CARL with an AI model for sentiment and relevance, and aggregates insider trades from CARLSMED, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Carlsmed (NASDAQ:CARL) discussed a CMS final rule issued July 31 that creates new MS-DRG codes for aprevo lumbar procedures, effective Oct. 1, 2026, replacing 11 codes. Management expects no material impact on 2H 2026 results. Q2 gross margin rose to 76.8% and GAAP net loss widened to $10.5M. Cash and investments were $89.3M at June 30.
5 min readCARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 carl-ex99_1.htm EX-99.1 EX-99.1 Carlsmed ® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 milli
4 min readThe article provides financial information for Carlsmed, Inc. (LS:A41CM7) on TradingView. It shows the total operating expenses for the company, accessible through various financial data providers like ICE Data Services and FactSet. The content primarily focuses on the display of operating expenses within the TradingView platform.
2 min readThis page provides financial statistics for Carlsmed, Inc. (LS:A41CM7), a company listed on the Lang & Schwarz Tradecenter. It details various annual and quarterly key financial stats and ratios, including valuation, profitability, liquidity, solvency ratios, and per-share metrics, although most data fields are currently listed as unavailable. The page serves as a hub for users to find market capitalization, P/E Ratio, EPS, ROI, and other financial information for Carlsmed.
2 min readCarlsmed, Inc. (NASDAQ:CARL) experienced a significant 26.4% drop in short interest in April, with the total short interest falling to 571,356 shares. Institutional investors have increased their holdings in the company, with OrbiMed Advisors LLC, Janus Henderson Group PLC, and Vanguard Group Inc. initiating or adding to their positions. Despite a "Hold" consensus rating and a target price of $19.67, analyst sentiment is mixed, with some firms trimming price targets while others maintain "Buy" ratings.
2 min readCarlsmed, Inc. (NASDAQ:CARL) has received a consensus "Hold" recommendation from five brokerages. The average 1-year price target is $21.33, with institutional investors recently increasing their stakes. The company's stock traded up 15.9% and beat quarterly earnings estimates.
3 min readCarlsmed, Inc. announced that a new study published in Global Spine Journal confirms its personalized spine implants significantly reduce reoperation rates in complex adult spinal deformity surgery by 74%. Despite this positive clinical news, the medical device company's stock (NASDAQ:CARL) has declined, even after reporting a 98% revenue increase to $13.1 million in Q3 2025 and launching its aprevo Technology Platform for cervical fusion surgeries. These developments highlight Carlsmed’s advancements in personalized spine treatment.
4 min readCarlsmed, Inc. (Nasdaq: CARL) announced that its Chairman and CEO, Mike Cordonnier, will present at the J.P. Morgan 2026 Healthcare conference on January 14th in San Francisco, CA. The company will also hold 1x1 investor meetings during the conference. Carlsmed is a medical technology company focused on AI-enabled personalized spine surgery solutions.
4 min readCARLSBAD, Calif., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Carlsmed, Inc. ( Nasdaq: CARL ) ( "Carlsmed" or the "Company" ) , a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and ...
3 min readCARLSBAD, Calif., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Carlsmed, Inc. ( Nasdaq: CARL ) ( "Carlsmed" or the "Company" ) , a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that effective after market close on September 22, 2025, it has been ...
3 min read
